Suppr超能文献

复发与再感染: fidaxomicin 或万古霉素治疗后的复发性艰难梭菌感染。

Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.

机构信息

Hines Veterans Affairs Hospital, Hines, IL 60141, USA.

出版信息

Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S104-9. doi: 10.1093/cid/cis357.

Abstract

Our study sought to compare the strain types of Clostridium difficile causing initial and recurrent episodes of C. difficile infection (CDI) in adult patients with a first episode of CDI or 1 prior episode of CDI within the previous 90 days. Strains originated from patients who had been entered into two phase 3 randomized clinical trials of fidaxomicin versus vancomycin. Isolates of C. difficile from the initial and recurrent episodes within 28 (± 2) days of cure of CDI were compared using restriction endonuclease analysis (REA) typing. Paired isolates were available from 90 of 194 (46%) patients with recurrent CDI. Patients with isolates available were significantly younger (P = .008) and more likely to be from Canadian sites (P = .0001), compared with patients without isolates. In 75 of 90 subjects (83.3%), the identical REA type strain was identified at recurrence and the initial episode (putative relapse). Early recurrences (0-14 days after treatment completion) were relapses in 86.7% and a new strain (reinfection) in 13.3%. Later recurrences (15-31 days after treatment) were relapses in 76.7% and reinfections in 23.3%. Mean time (± standard deviation) to recurrence was 12.2 (± 6.4) days for relapses and 14.7 (± 6.8) days for reinfections (P = .177). The most common BI/NAP1/027 group and the previous US epidemic REA group J/NAP2/001 had a significantly higher combined rate of recurrence with the same strain (relapse), compared with the other REA groups (39 of 42 [93%] vs 36 of 48 [75%], respectively; P = .023). We found a higher than historic rate of recurrent CDI caused by the same isolate as the original episode, a finding that may be related to the relatively short observation period in this study and the high frequency of isolation of epidemic strains, such as groups BI and J, for which relapse rates may be higher than for other REA groups. Caution in generalizing these observations is required, because the patients studied were younger and more likely to be from Canadian sites than were patients with recurrence who did not provide isolates.

摘要

我们的研究旨在比较导致初发性和复发性艰难梭菌感染(CDI)的艰难梭菌菌株类型,这些患者患有初发性 CDI 或在过去 90 天内有 1 次 CDI 发作。菌株源自参加了两项 fidaxomicin 与万古霉素对比的 3 期随机临床试验的患者。使用限制性内切酶分析(REA)分型比较了在 CDI 治愈后 28(±2)天内的初发和复发感染的艰难梭菌分离株。90 例(46%)复发性 CDI 患者中可获得配对分离株。与未提供分离株的患者相比,可提供分离株的患者年龄明显更小(P=0.008),并且更可能来自加拿大的研究地点(P=0.0001)。在 90 例患者中的 75 例(83.3%),复发和初发感染中鉴定出相同的 REA 型菌株(假定复发)。早期复发(治疗完成后 0-14 天)中 86.7%为复发,13.3%为新菌株(再感染)。晚期复发(治疗后 15-31 天)中 76.7%为复发,23.3%为再感染。复发的平均时间(±标准差)为 12.2(±6.4)天,再感染为 14.7(±6.8)天(P=0.177)。最常见的 BI/NAP1/027 组和先前的美国流行 REA 组 J/NAP2/001 与相同菌株(复发)的复发率显著更高,与其他 REA 组相比(分别为 42 例中的 39 例[93%]和 48 例中的 36 例[75%];P=0.023)。我们发现,由与初始感染相同的分离株引起的复发性 CDI 的发生率高于历史数据,这一发现可能与本研究的观察期相对较短以及 BI 和 J 等流行株的高分离率有关,这些菌株的复发率可能高于其他 REA 组。需要谨慎推广这些观察结果,因为研究患者比未提供分离株的复发性 CDI 患者年龄更小,并且更可能来自加拿大的研究地点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4099/3388025/2353ad71fbd9/cis35701.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验